Torrent Pharmaceuticals has announced that its manufacturing facility in Indrad, Gujarat, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), with a classification of “Voluntary Action Indicated” (VAI). This marks the successful conclusion of the inspection that took place from June 3 to June 12, 2024.
The company previously communicated the initiation of the inspection and has now confirmed that the USFDA has officially closed the inspection process. The VAI classification allows Torrent Pharma to continue its operations while addressing any observations noted during the inspection.
This development is significant for Torrent Pharma as it strengthens its position in the regulated international markets, particularly the US, where compliance with stringent regulatory standards is crucial for product approvals. The company remains committed to ensuring high-quality manufacturing practices and addressing any necessary improvements to enhance its operational capabilities.
Torrent Pharma’s successful closure of this inspection is expected to bolster investor confidence and pave the way for future growth opportunities in the pharmaceutical sector.